Lofexidine

  • TRADE NAMES: BritLofex (Britannia); Lucemyra (US WorldMeds, LLC)
  • INDICATIONS: mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
  • CLASS: Adrenergic alpha2-receptor agonist
  • HALF-LIFE: ~12 hours

FDA APPROVAL DATE: 05/16/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Methadone, Naltrexone

PREGNANCY CATEGORY: N/A
The safety of lofexidine in pregnant women has not been established.

Our database has 17 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
OTIC
OTHER


Page last updated 06/27/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric